Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02475681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02475681 · ClinicalTrials.gov record · last posted 2026-08-25

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Name: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL — clinical trial record (NCT02475681)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ElevateTN

StatusActive, Not Recruiting

PhasePhase 3

SponsorAcerta Pharma BV

Started2015-06-26

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria. 2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)

Protocol amendment history 1 change detected by DataLookout

2026-08-26

Completion pushed: 2025-09-30 → 2026-09-15

Trial Details

NCT Number	NCT02475681
Lead Sponsor	Acerta Pharma BV
Conditions	Chronic Lymphocytic Leukemia
Enrollment	535 participants
Start Date	2015-06-26
Primary Completion	2019-02-08 (estimated)
Study Completion	2026-09-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-25